about
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patientsPrognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma.High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experienceInterim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trialsBrentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens.Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series.Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: a case report and review of the literature.Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.Weight status and body image perception in Italian children.Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).Is it really possible to cure hairy cell leukemia patients only with frontline therapy?Primary ocular adnexal lymphomas: a retrospective study of 25 patients.Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine.Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis.Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: bridge to transplant.Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report.Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma.Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma.The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients.
P50
Q33390098-2B5F18D0-94A8-4ADE-87C1-C9E4E9AFDFCBQ33396803-AB7AF120-F509-4E6B-8510-625F5E257837Q33404090-C529E759-AB44-43E4-9A81-0AB1513ECD28Q33431457-9CAE8391-60F4-481A-BD22-28C5A8226143Q33568389-618780B8-894D-4811-B940-76CF68A4A6DAQ33829759-182173DB-ED82-4325-AA12-30E10FDFEAD0Q35836477-55979D4D-5E7E-4D08-BF34-1707AAA2B661Q35925639-75FD8957-512B-4B17-B0B5-EBBC9CF46D78Q36371623-E7C05ABA-5F22-4CE1-B814-97D9B0BB0A14Q37045536-195E22CD-C908-4917-BA00-3A958320267FQ37060652-844287E6-8551-4BE3-B3F8-7277E1008600Q37216325-EB0744CE-3C72-4D41-A4E3-234DB3734779Q38065131-098C435F-F56C-44B7-A120-D0CDDDA897FFQ38067963-132AAF54-D51B-4A3C-AAC7-E261B9540201Q38784718-D0D22625-7ED7-4EA4-94C9-5F8FA1468365Q39386942-7D8FFFE3-3F52-4B80-AB39-FA554AA9D36EQ39530535-1747CD88-F848-412F-9368-C1D9FA40DBD1Q40135708-7A4DDB37-C569-49B0-954F-E8DBDA76D4C8Q40144116-8A5A6E53-2C31-4F01-A9DE-60D384373153Q41117363-53276570-B44F-4122-AF08-E33C6D1ECCCFQ43249154-779BFC34-18CF-4746-9821-AAF050C8953FQ43457873-7F09DDE0-98E5-401A-85F3-FE396A3E4F4EQ43531631-A86C4E98-0B2E-4F07-946F-B15DF2B0631AQ43807672-F80B6974-3370-4704-91C8-9AC85120C010Q44166662-FC444A46-8C48-4AD8-AD91-533DE1C3FBD8Q46061398-0C0DB58E-7E76-4823-A571-2DFF60EDCE65Q46698290-096F2ECC-24F9-4F99-961F-91917D7E93A4Q47093592-2485DF03-2048-408D-B61E-1684006B3BEAQ47130656-9F14520B-CF36-4FCA-B36A-16CD4EBDB7FBQ47658636-624F3223-ED68-4932-A484-7AC86FA391E1Q47672298-9CB28E34-B828-41BB-8F3B-C465C9F540B2Q47926080-A628A65A-898C-428D-85FF-FC3731A8D74EQ48088431-BCA6C4B5-6898-4DDE-8339-E6DEBB097D7DQ48178853-78DF9466-DC0A-470F-8485-0BBA67B65C07Q48582114-49872240-44FA-47BE-AE90-4524D4C21FBEQ51039125-3B498536-FB25-4FD9-ABD6-3F019AA07C6EQ51161624-F6416E9A-43BE-485F-B936-A498B171A650Q52576600-ED2CE153-CF14-4D0A-B3E5-0507336D716EQ52944951-97A97934-E051-4F9E-9996-A5159A8F646FQ53049216-53330668-06DF-4095-BAE7-85B4EC7FF199
P50
description
researcher ORCID ID = 0000-0003-4225-4626
@en
wetenschapper
@nl
name
Lisa Argnani
@ast
Lisa Argnani
@en
Lisa Argnani
@es
Lisa Argnani
@nl
type
label
Lisa Argnani
@ast
Lisa Argnani
@en
Lisa Argnani
@es
Lisa Argnani
@nl
prefLabel
Lisa Argnani
@ast
Lisa Argnani
@en
Lisa Argnani
@es
Lisa Argnani
@nl
P106
P1153
25026936900
P21
P31
P496
0000-0003-4225-4626